# Hims & Hers Surges On 'Surprising And Inevitable' Deal With Eli Lilly

> **Open Intelligence Dossier** · First detected: 2026-11-06 21:00 UTC · Category: Business

## Executive Summary
Eli Lilly has struck a deal allowing Hims & Hers Health to sell its obesity drugs Zepbound and Foundayo directly on its platform.

## Intelligence Brief
According to Reuters, Eli Lilly announced a partnership on Friday allowing Hims &amp; Hers Health to offer its obesity medications Zepbound and Foundayo directly on the telehealth platform. Previously, patients could only access Lilly drugs on Hims &amp; Hers by leaving the site and visiting Lilly&#039;s own cash-pay platform, LillyDirect. Reuters reported that this move sent the telehealth company&#039;s shares up by more than 7% in premarket trading. MarketWatch and Investor&#039;s Business Daily also noted the stock rally following the GLP-1 deal. This agreement aligns Lilly with its Danish rival Novo Nordisk, which has been selling Wegovy and Ozempic through Hims &amp; Hers since March after previously suing the telehealth company over compounded versions. Leerink Partners analyst Michael Cherny called the Lilly partnership a clear positive, noting to Reuters that the deal completes Hims &amp; Hers&#039; process to secure access to the two leading GLP-1 drugmakers following its exit from mass compounding. Ilya Yuffa, president of Lilly USA, told Reuters that previously the ease and ability for someone on the platform to get Lilly medicine was not fully straightforward. Yuffa stated that any friction point for consumers increases the chance of abandonment. As part of the agreement, Yuffa told Reuters that Hims &amp; Hers has agreed to stop selling any compounded versions or knockoffs of Lilly&#039;s obesity medications. Self-pay pricing starts at $299 per month for the injectable GLP-1 Zepbound and $149 per month for the oral Foundayo, matching prices on LillyDirect. Reuters reported that Novo&#039;s drugs on the platform start at $199 per month for the Wegovy injector pen and $149 per month for the Wegovy pill. According to Lilly, roughly 40% to 45% of Zepbound sales go through self-pay channels. Analysts told Reuters that Hims &amp; Hers could receive a boost next year if employers drop weight-loss drug coverage to cut costs. Reuters noted that Lilly recently raised its full-year revenue forecast by $5 billion due to booming demand for its injectable weight-loss treatments, driving the company to a $1.2 trillion market valuation.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| www.tokenpost.com | LifeMD Adds Mail-Order Option for Lilly’s Zepbound and Foundayo | [Source Link](https://news.google.com/rss/articles/CBMiWEFVX3lxTE5UYWFvMGJnSE5oU3ZTS2xmZDhKbm16NFE5aHMzX0N1YWZ2YlZJY3h0NzlVRVBCYU5BN0tOdUFJT1NaaW9JUUNOVHg4cGdMVHVObHdnamNZYlU?oc=5) |
| Simply Wall St | Is Hims & Hers Health (HIMS) A Bargain After Its Lilly Deal? | [Source Link](https://news.google.com/rss/articles/CBMiygFBVV95cUxONVJHX2ViT0tqYnFkNjRLTldEVExmNmEwaEo0VGtvS1lFeEVQTUlUb19EOXotSjh0VnhHV2dkNVFIcmFia21QMFhFN1J1WVNGSnRyRmJXQmh6RDE0RVBLNTZmN200Yk5PQmtCV25NV2tYb3ZfRFpjYjJvX0dOeTFHSndILUpxbUQySkxucV9MZnhhWmdBSGZKM3Y4R2pRZEpwaTZPdkdqY3BVLVFLQjl4QTNFME5QN3FYWDU0ZWMtR25PaHVZWnJfcTlB0gHPAUFVX3lxTE16dTh5ZlhwZnlTekhCNFFJNV9hUS1sSUtUd3EtR1lOSjFqQ1o0YkE2ZHBQSHk4OG5hbjdBWTltVWVQVkhJNkFFNVhwRkh5cEMzT2ViNHpBb2NQVU13akJ0MmpmZEo5SXRQT3V2a0dTbUVESXVmanNtMzNqbEh6OVczQW85MW5JZzZ) |
| qz.com | Eli Lilly, Hims & Hers reach deal on direct obesity drug sales | [Source Link](https://news.google.com/rss/articles/CBMid0FVX3lxTE9IOUUtVVNaWVBOM3RDYTlpX3pJdjI3TG1SMzhzZmMyZ0FObHZVMkpFZEp1MGNuZG1Cd0t5em95UjBWUmRXNWg1cGhuVFo0OE83ZFF2UGU3cmlVQ0xDOUlaM3JRMUtYb3I0RVpOSXJvdmh2X1FaeFBF?oc=5) |
| Barron's | Why Hims & Hers Health Stock Was in Dire Need of This Eli Lilly Agreement | [Source Link](https://news.google.com/rss/articles/CBMihgFBVV95cUxNRlI5c1lKOTdrclVablJaY25QbmhUNkhCT050bVFnVnV4bnR0aWo5dGdUWjlCaUZFc0NmX1dYRW5JdW55dElWaThvMk5FMGU4QlduNGlpd1dKcVA4SGdHVjJBYUpEejlyUlVaQVlKV21YTlJKdWJNcmZxWUZNV1hjc3dqU0lKZw?oc=5) |
| Fierce Healthcare | Hims & Hers inks deal with Eli Lilly to offer branded weight loss drugs | [Source Link](https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUkNISENyR1Z1N0JqLTRsaDhnU0lpbFVmajNHSUhBZzZSUEtHdy1GNy1ia1V3dklOakdqUVZETDhKdTVxc0lGRXItWXh6bEd0SWRPakU5am5kUWxad1lDWFgtOVdRNEZHejBqZGtOS3NhZTJXbTNXOVJaZ0FVOGVlQWc0UC1DMXZCa3c3NlBpVF9TNnV6dGdVVDlnX19qLTFKdk1sbWRPMkZFZw?oc=5) |
| FirstWord Pharma | Lilly turns to Hims & Hers to boost access to obesity drugs in US | [Source Link](https://news.google.com/rss/articles/CBMiU0FVX3lxTFA4RldKVjlidS03VlVtVU5JbEpHRmJWNy1YX3ZUaWtPUmROX2RjVUFzVHJ2RXpTb1BvV3VlRDk1MUk2ZHNrdHFEeXhSdkxkaEdmUnE0?oc=5) |
| PR Newswire | Lilly and Hims & Hers expand access to FDA-approved Lilly medicines | [Source Link](https://news.google.com/rss/articles/CBMivwFBVV95cUxQSWVaQnZCVnZucmd0MzNZRnR6RG5zTmp2d3JZTjMtSWtkNVRORFdYLUQ4MF9IaldWeUFOLWJUSFhuR1RFZE9Uc1cydU8yTmU4Rk9lUlktcTZzc2ZiYVpGUzdwQy1qOVBtOWJLT29RckE5dm9DRUNCbV9uN25xQ2ZpcVh1MFdpUndDU2NpMGRkSWhoUHR3YU9nUXdjNE9lQVNwWGF1STRvQTNDTkczeUktM3BBRFVJOXlDZGFNWTlDYw?oc=5) |
| Bloomberg.com | Lilly, Hims Join Forces to Reach More Weight-Loss Drug Patients | [Source Link](https://news.google.com/rss/articles/CBMiswFBVV95cUxOYUNVY0tPR28yc2wxdGFBX1ZsNC1pNHpjaDc4Wk1fRG8xSzlST1l6RjFnRDVJQ2F3MWI1SWNUQTlNbEFvd2FYOVpHMk1PZm5GSGYwTmFPQWVmU182cHJlck1kTTlWcjZkYnU0Qm5wN2M3MU80NGg1VEkyZnhnZEFTOGpDT1pSQ3lMSGpRVkh1VFYzT3oteTJoejQ3a0Q4Zlpfb2FGRWxUY2w2elA2dmEtcG5YNA?oc=5) |
| MarketWatch | Hims & Hers struck a GLP-1 deal with Lilly. Its stock is rallying. | [Source Link](https://news.google.com/rss/articles/CBMiqAFBVV95cUxQX0xEdUpCSUEzOG5jcmN5cVY0dkZMU3FhQzgxNVZ1ZDVMZkpzeDNXOWxlZXFvOEplS3puck1mYW1FeFlDQl9pN2dXdTFWb0FSUkw0VnJycXFtb1E0MDBQZ3RVdFhZMmFkeW1nVmFBeHdIZ3VybnBxQTJ6Yjl5SG1HUjBFMk9ncENQeTZJNUxab3NFR192ZUdGdUJINlVfYXI0VEVZbVNGdDg?oc=5) |
| Hims & Hers Newsroom | Lilly and Hims & Hers Expand Access to FDA-Approved Lilly Medicines | [Source Link](https://news.google.com/rss/articles/CBMinAFBVV95cUxPV0haMDh2Z0tvLXROVWtPLUVpX0xfSldnWnBYWWZoTldpVjd4c19vcVkzeVlocEhnTUVQdHBlczRsTXdHOU4ySDJYTGVtN0poVUVpTFFTb2J4aHR6RHZKTHBoTWdRZFJ0WFZDNy1LY0xJRWNEU1JwTHlLVFdoZ014OEx0b284Uy10bGhsYXN3UW5tZXFtVjBpZ1lIWEc?oc=5) |
| Reuters | Lilly to sell obesity drugs directly on Hims & Hers site | [Source Link](https://news.google.com/rss/articles/CBMiowFBVV95cUxNakJ0R0VKODFoU09YcW1WRDVISTFsa3QzWk9hMWYyMHJYN0x6NmhvaTMtczJxaENnNE1STlhYOG1YRUU4UlN1dDl5Z0FlODVYc0J3a3hZTkR4MVlWYzNsc3RvWF9FM0JMVlpYQ2dTbU02QkV1aklrQmxueF9YUmxkenpwb0NDdEIzcGxpZElETTYyLVhJQWFjbE9qY3EwUE9oNDZz?oc=5) |
| Investor's Business Daily | Hims & Hers Surges On 'Surprising And Inevitable' Deal With Eli Lilly | [Source Link](https://news.google.com/rss/articles/CBMiowFBVV95cUxQdzRRQ3d0blNWZmNRZ2QycWFQaVVhME8tVG9fLXVrOTFQSFFGNjl4aHFuVmxBWlE2bk1MMFZ2Ym5VNlQ0TjU5WU95eHhMYlU4NHVsd0hPdGJ6Y2JiMFlhS0NnSERzRVJreVpTSGw0WFVHVHJBcUV6VWh5QXRPaURyUXQ1ZkpaTWtFc2hUMm5yd0U5RU1mUnVxemZUWG13dXVxOHdr?oc=5) |

---
*Canonical Source: https://pulse.byoaiapps.com/trend/2026-11-06/hims-hers-surges-on-surprising-and-inevitable-deal-with-eli-lilly*
